Gaurav Aggarwal is a Managing Partner at Vivo Capital with over two decades of experience in life sciences investing. His background includes roles as Chief Business Officer at Ocera Therapeutics and investor at firms like JPMorgan Partners. He holds an M. D. from Columbia University and a B. S. from Cornell University.
His unique qualification as a medical doctor combined with his extensive venture capital experience gives him a distinct perspective on biopharmaceutical and medical device investments.
Gaurav Aggarwal
Chief Investment Officer - Opportunity Fund at Vivo Capital
Palo Alto, California, United States
Overview
Topics They Care About
VC in Public Markets
Applies a "venture capital mindset to publicly traded biotech companies, " focusing on long-term value creation rather than short-term market fluctuations.
Biotech Corporate Strategy
He has extensive experience in financial strategy, business development, and capital formation from his board memberships and his time as Chief Business Officer at Ocera Therapeutics.
Life Sciences Investing
Has invested in the life sciences sector for over 20 years, focusing on biopharmaceutical and medical device companies across various stages of development.
Media Appearances
Gaurav Aggarwal – Vivo Capital | SuperReturn North America Speaker. Featured in SuperReturn North America (Inforaconnect)
Work History
1-2021
Chief Investment Officer - Opportunity Fund at Vivo Capital
10-2016
Managing Director at Vivo Capital
4-2014 - 10-2016
Chief Business Officer at Ocera Therapeutics, Inc.
1-2013 - 12-2013
Managing Director at Investor Growth Capital
3-2004 - 7-2006
Associate at JP Morgan Partners
Partner at Panorama Capital
Education
1994 - 2000
Doctor of Medicine (MD) from Columbia University Vagelos College of Physicians and Surgeons
1990 - 1994
Bachelor's degree from Cornell University
More Information
Social Presence :
Prographics :
Exp : 15
Location : Palo Alto, California, United States
Job Level : Leadership
Designation : Chief Investment Officer - Opportunity Fund at Vivo Capital
